De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)

doi:10.1186/s13012-018-0833-7

Multicenter Study

. 2018 Nov 29;13(1):144.

doi: 10.1186/s13012-018-0833-7.

De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)

Ted A Skolarus^{1

2}, Sarah T Hawley³, Daniela A Wittmann⁴, Jane Forman³, Tabitha Metreger³, Jordan B Sparks³, Kevin Zhu³, Megan E V Caram^{3

5}, Brent K Hollenbeck⁴, Danil V Makarov^{6

7}, John T Leppert^{8

9}, Jeremy B Shelton¹⁰, Vahakn Shahinian¹¹, Sriram Srinivasaraghavan¹², Anne E Sales^{3

13}

Affiliations

¹ VA HSR&D Center for Clinical Management Research, VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA. tskolar@med.umich.edu.
² Department of Urology, Dow Division of Health Services Research, University of Michigan Medical School, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA. tskolar@med.umich.edu.
³ VA HSR&D Center for Clinical Management Research, VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA.
⁴ Department of Urology, Dow Division of Health Services Research, University of Michigan Medical School, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA.
⁵ Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
⁶ Departments of Urology and Population Health, NYU Langone Medical Center, New York City, NY, USA.
⁷ VA New York Harbor Healthcare System, 423 E. 23rd St, New York City, NY, 10010, USA.
⁸ Department of Urology, Stanford University School of Medicine, Grant Building, S-287, 300 Pasteur Drive, Stanford, CA, 94305, USA.
⁹ VA Palo Alto Healthcare System, Palo Alto, CA, USA.
¹⁰ VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd, Los Angeles, CA, 90073, USA.
¹¹ Division of Nephrology, University of Michigan Medical School, Medical School, 1500 E. Medical Center Dr, Ann Arbor, MI, 48109, USA.
¹² University of Michigan Ross School of Business, 701 Tappan Street, Ann Arbor, MI, 48109, USA.
¹³ Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA.

PMID: 30486836
PMCID: PMC6262964
DOI: 10.1186/s13012-018-0833-7

Multicenter Study

De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)

Ted A Skolarus et al. Implement Sci. 2018.

. 2018 Nov 29;13(1):144.

doi: 10.1186/s13012-018-0833-7.

Authors

Affiliations

¹ VA HSR&D Center for Clinical Management Research, VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA. tskolar@med.umich.edu.
² Department of Urology, Dow Division of Health Services Research, University of Michigan Medical School, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA. tskolar@med.umich.edu.
³ VA HSR&D Center for Clinical Management Research, VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA.
⁴ Department of Urology, Dow Division of Health Services Research, University of Michigan Medical School, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA.
⁵ Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
⁶ Departments of Urology and Population Health, NYU Langone Medical Center, New York City, NY, USA.
⁷ VA New York Harbor Healthcare System, 423 E. 23rd St, New York City, NY, 10010, USA.
⁸ Department of Urology, Stanford University School of Medicine, Grant Building, S-287, 300 Pasteur Drive, Stanford, CA, 94305, USA.
⁹ VA Palo Alto Healthcare System, Palo Alto, CA, USA.
¹⁰ VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd, Los Angeles, CA, 90073, USA.
¹¹ Division of Nephrology, University of Michigan Medical School, Medical School, 1500 E. Medical Center Dr, Ann Arbor, MI, 48109, USA.
¹² University of Michigan Ross School of Business, 701 Tappan Street, Ann Arbor, MI, 48109, USA.
¹³ Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA.

PMID: 30486836
PMCID: PMC6262964
DOI: 10.1186/s13012-018-0833-7

Abstract

Background: Men with prostate cancer are often castrated with long-acting injectable drugs termed androgen deprivation therapy (ADT). Although many benefit, ADT is also used in patients with little or nothing to gain. The best ways to stop this practice are unknown, and range from blunt pharmacy restrictions to informed decision-making. This study will refine and pilot two different de-implementation strategies for reducing ADT use among those unlikely to benefit in preparation for a comparative effectiveness trial.

Methods/design: This innovative mixed methods research program has three aims. Aim 1: To assess preferences and barriers for de-implementation of chemical castration in prostate cancer. Guided by the theoretical domains framework (TDF), urologists and patients from facilities with the highest and lowest castration rates across the VA will be interviewed to identify key preferences and de-implementation barriers for reducing castration as prostate cancer treatment. This qualitative work will inform Aim 2 while gathering rich information for two proposed pilot intervention strategies. Aim 2: To use a discrete choice experiment (DCE), a novel barrier prioritization approach, for de-implementation strategy tailoring. The investigators will conduct national surveys of urologists to prioritize key barriers identified in Aim 1 for stopping incident castration as localized prostate cancer treatment using a DCE experiment design. These quantitative results will identify the most important barriers to be addressed through tailoring of two pilot de-implementation strategies in preparation for Aim 3 piloting. Aim 3: To pilot two tailored de-implementation strategies to reduce castration as localized prostate cancer treatment. Building on findings from Aims 1 and 2, two de-implementation strategies will be piloted. One strategy will focus on formulary restriction at the organizational level and the other on physician/patient informed decision-making at different facilities. Outcomes will include acceptability, feasibility, and scalability in preparation for an effectiveness trial comparing these two widely varying de-implementation strategies.

Discussion: Our innovative approach to de-implementation strategy development is directly aligned with state-of-the-art complex implementation intervention development and implementation science. This work will broadly advance de-implementation science for low value cancer care, and foster participation in our de-implementation evaluation trial by addressing barriers, facilitators, and concerns through pilot tailoring.

Trial registration: ClinicalTrials.gov Identifier: NCT03579680 , First Posted July 6, 2018.

Keywords: Androgen deprivation therapy (ADT); Behavior change; Castration; Choosing wisely; De-implementation; Decision-making; Discrete choice; Formulary restriction; Implementation science; Intervention; Low value care; Stakeholder.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study has been approved by the VA Ann Arbor Healthcare System IRB (IRB-2017-1047) and the University of Michigan IRB (HUM00133932). As this study is conducted solely by phone and by mail and is considered minimal risk, a waiver of documentation of signed informed consent and HIPAA Authorization was approved. Verbal informed consent is obtained for all patients participating in the research. Further information and documentation on IRB approval is available upon request.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests. Dr. Skolarus is a prostate cancer survivorship author for UpToDate™.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

**Fig. 1**
Conceptual model for de-implementation of low value prostate cancer care

See this image and copyright information in PMC

Cited by

Unpacking overuse of androgen deprivation therapy for prostate cancer to inform de-implementation strategies.
Skolarus TA, Hawley ST, Forman J, Sales AE, Sparks JB, Metreger T, Burns J, Caram MV, Radhakrishnan A, Dossett LA, Makarov DV, Leppert JT, Shelton JB, Stensland KD, Dunsmore J, Maclennan S, Saini S, Hollenbeck BK, Shahinian V, Wittmann DA, Deolankar V, Sriram S. Skolarus TA, et al. Implement Sci Commun. 2024 Apr 9;5(1):37. doi: 10.1186/s43058-024-00576-x. Implement Sci Commun. 2024. PMID: 38594740 Free PMC article.
Applying the behavior change wheel to design de-implementation strategies to reduce low-value statin prescription in primary prevention of cardiovascular disease in primary care.
Sanchez A, Elizondo-Alzola U, Pijoan JI, Mediavilla MM, Pablo S, Sainz de Rozas R, Lekue I, Gonzalez-Larragan S, Llarena M, Larrañaga O, Helfrich CD, Grandes G. Sanchez A, et al. Front Med (Lausanne). 2022 Oct 13;9:967887. doi: 10.3389/fmed.2022.967887. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36314033 Free PMC article.
A scoping review of de-implementation frameworks and models.
Walsh-Bailey C, Tsai E, Tabak RG, Morshed AB, Norton WE, McKay VR, Brownson RC, Gifford S. Walsh-Bailey C, et al. Implement Sci. 2021 Nov 24;16(1):100. doi: 10.1186/s13012-021-01173-5. Implement Sci. 2021. PMID: 34819122 Free PMC article.
Reducing the frequency of hand hygiene to maintain skin integrity among nurses in the growing care unit: A pilot study.
Tano M, Kohta M, Yano Y, Sugama J. Tano M, et al. Fujita Med J. 2025 Aug;11(3):135-141. doi: 10.20407/fmj.2024-029. Epub 2025 Apr 17. Fujita Med J. 2025. PMID: 40777146 Free PMC article.
Creation of a theoretically rooted workbook to support implementers in the practice of knowledge translation.
Fahim C, Courvoisier M, Somani N, De Matas F, Straus SE. Fahim C, et al. Implement Sci Commun. 2023 Aug 18;4(1):99. doi: 10.1186/s43058-023-00480-w. Implement Sci Commun. 2023. PMID: 37596659 Free PMC article.

See all "Cited by" articles

References

1. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98(12):839–845. doi: 10.1093/jnci/djj230. - DOI - PMC - PubMed
1. Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol. 2011;29(6):647–653. doi: 10.1016/j.urolonc.2009.09.004. - DOI - PMC - PubMed
1. Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W, 3rd, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64(4):225–249. doi: 10.3322/caac.21234. - DOI - PubMed
1. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19):1822–1832. doi: 10.1056/NEJMsa0910784. - DOI - PubMed
1. Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL. Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate Cancer. Eur Urol. 2015;68(5):805–811. doi: 10.1016/j.eururo.2015.03.021. - DOI - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

[1] Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98(12):839–845. doi: 10.1093/jnci/djj230. - DOI - PMC - PubMed

[2] Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98(12):839–845. doi: 10.1093/jnci/djj230. - DOI - PMC - PubMed

[3] Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol. 2011;29(6):647–653. doi: 10.1016/j.urolonc.2009.09.004. - DOI - PMC - PubMed

[4] Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol. 2011;29(6):647–653. doi: 10.1016/j.urolonc.2009.09.004. - DOI - PMC - PubMed

[5] Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W, 3rd, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64(4):225–249. doi: 10.3322/caac.21234. - DOI - PubMed

[6] Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W, 3rd, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64(4):225–249. doi: 10.3322/caac.21234. - DOI - PubMed

[7] Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19):1822–1832. doi: 10.1056/NEJMsa0910784. - DOI - PubMed

[8] Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19):1822–1832. doi: 10.1056/NEJMsa0910784. - DOI - PubMed

[9] Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL. Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate Cancer. Eur Urol. 2015;68(5):805–811. doi: 10.1016/j.eururo.2015.03.021. - DOI - PMC - PubMed

[10] Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL. Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate Cancer. Eur Urol. 2015;68(5):805–811. doi: 10.1016/j.eururo.2015.03.021. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)

Affiliations

De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)

Authors

Affiliations

Abstract

Conflict of interest statement

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher’s Note

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Medical